On 31 May, 2016, Promore Pharma completed a Scientific Advice Meeting with the Medical Products Agency in Sweden, regarding its clinical development initiative based on PXL01 for prevention of post-surgical adhesions.
The company obtained positive feedback for its development plans for the PXL01-based product, and will continue the planning of its PHSU-003 clinical trial in the EU based in this input.